Company intelligence / Profile preview

Hangzhou Zhihe Dangu Biotechnology

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

SmartNucl (Hangzhou Zhihe Dangu Biotechnology) is a clinical-stage biopharmaceutical company specializing in the development of next-generation radiopharmaceuticals. The company leverages its proprietary nanobody (single-domain antibody) platform to create targeted imaging and therapeutic agents for oncology. Its lead candidate, SNC-002, is a PD-L1-targeting radiopharmaceutical designed for non-invasive PET/SPECT imaging to predict immunotherapy response. SmartNucl aims to provide precision medicine solutions by combining diagnostic imaging with targeted radionuclide therapy (theranostics).

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalNanobody therapyMonoclonal antibody fragment
Industry: Biotech

Beyond the preview

Go deeper on Hangzhou Zhihe Dangu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Zhihe Dangu Biotechnology.

Explore the full profile